Sign up
Pharma Capital

Shares of CymaBay Therapeutics gain after study signals Seladelpar treatment shows 'efficacy'

The company now expects drug to advance to Phase 3 study
Assorted pills on table
The shares gained 11% on the study news

Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) rose after the company said a study of its Seladelpar treatment for an autoimmune disease of the liver showed “compelling efficacy and tolerability.”

The stock advanced 11% to US$13.44.

The results from the Phase 2 study “support the potential for improved efficacy and better tolerability over existing second-line therapy,” the company said in a statement. CymaBay now expects the treatment to advance to Phase 3 in the second half of the year.

 



Register here to be notified of future CBAY Company articles
View full CBAY profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.